Skip to content
AVTXAvalo Therapeutics, Inc.

Earnings

When Avalo Therapeutics, Inc. reports, what it reported each quarter, and how the stock took the results.

51 quarters. Mar 31, 2014 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Mar 22, before the open

Mon, Mar 22, 2027in 124 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 5 – Apr 1

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
—
Revenue, change from a year earlier: Q3 2025 −100.0%, Q4 2024 −66.3%, Q3 2024 +5.5%, Q2 2024 −100.0%
Net income
-$13.72M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2025$0.00−100.0% vs Q3 2024

Latest results

  1. Q3 2026Nov 5, 2026, before the openThe release6.6%by the close of Nov 5
    Revenue
    —
    —
    Net income
    -$18.95M
    N/M
    EPS
    -$0.34
    N/M
    Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company focused on developing therapies targeting the IL-1β pathway for immune-mediated inflammatory diseases, today reported financial results for the third quarter of 2026 and provided a business update.
  2. Q2 2026Aug 6, 2026, before the openThe release0.8%by the close of Aug 6
    Revenue
    —
    —
    Net income
    -$36.36M
    N/M
    EPS
    -$0.83
    N/M
  3. Q1 2026May 13, 2026, before the openThe release0.5%by the close of May 13
    Revenue
    —
    —
    Net income
    -$19.63M
    N/M
    EPS
    -$0.98
    N/M
  4. Q4 2025Mar 23, 2026, before the openThe release+0.7%by the close of Mar 23
    Revenue
    —
    —
    Net income
    -$13.72M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 5, 2026 · pre-marketNov 5, 202636 d10-Q——-$0.346.6%
Q2 2026Jun 30, 2026Aug 6, 2026 · pre-marketAug 6, 202637 d10-Q——-$0.830.8%
Q1 2026Mar 31, 2026May 13, 2026 · pre-marketMay 13, 202643 d10-Q——-$0.980.5%
FY 2025
Q4 2025derivedDec 31, 2025Mar 23, 2026 · pre-marketMar 23, 202682 d10-K———+0.7%
Q3 2025Sep 30, 2025Nov 6, 2025 · pre-marketNov 6, 202537 d10-Q$0.00−100.0%-$2.196.2%
Q2 2025Jun 30, 2025Aug 7, 2025 · pre-marketAug 7, 202538 d10-Q——-$1.92+0.5%
Q1 2025Mar 31, 2025May 12, 2025 · pre-marketMay 12, 202542 d10-Q——-$1.255.9%
FY 2024
Q4 2024derivedDec 31, 2024Mar 20, 2025 · pre-marketMar 20, 202579 d10-K$192.00K−66.3%—+5.0%
Q3 2024Sep 30, 2024Nov 7, 2024 · pre-marketNov 7, 202438 d10-Q$249.00K+5.5%-$2.832.6%
Q2 2024Jun 30, 2024Aug 12, 2024 · pre-marketAug 12, 202443 d10-Q$0.00−100.0%-$14.07—
Q1 2024Mar 31, 2024May 13, 2024 · pre-marketMay 13, 202443 d10-Q$0.00−100.0%-$141.14—
Earlier years, FY 2014 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 5, 2026000057
10-QAug 6, 2026000049
10-QMay 13, 2026000033
10-KMar 23, 2026000011
10-QNov 6, 2025000018
10-QAug 7, 2025038575
10-QMay 12, 2025024436
10-KMar 20, 2025013986
10-QNov 7, 2024045965
10-QAug 12, 2024036591

Provenance

ProvenanceData status and checks

Avalo Therapeutics, Inc. · CIK 1534120 · Engraved from SEC EDGAR